|Bid||55.32 x 800|
|Ask||55.93 x 1800|
|Day's range||54.02 - 55.84|
|52-week range||36.15 - 64.94|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||67.82|
|Forward dividend & yield||1.40 (2.58%)|
|1y target est||59.10|
Canada's two most populous provinces on Friday moved to clamp down further on social gatherings in a bid to slow a second wave of coronavirus infections that since the start of the pandemic now total more than 150,000 nationwide. Premier Doug Ford, whose government has already slashed the size of permitted gatherings indoor and outdoors, repeated his concerns that the majority of new cases were in people under 40. Health officials in Canada have been making increasingly gloomy comments in recent days.
European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters. AstraZeneca has secured the European Union's backing in a confidential agreement which reflects the lower price sought by the British drugmaker, the official said. Unexpected side-effects after a drug has regulatory approval are rare, but the speed at which a COVID-19 vaccine is being pursued increases the risks of unforeseen conditions.
President Donald Trump has fanned new concerns over the politicization of coronavirus vaccine approvals, suggesting he could block stricter guidance from the FDA.